NSRX is tracked by BiotechSign with a latest available catalyst score of 37/100 and grade D. The page summarizes available signal categories and recent signal records, including FDA-event, insider, clinical-trial, short-interest, dilution, and source-backed publication signals when available, with data refreshed on 2026-08-17.
As of 2026-08-17, Nasus Pharma Ltd. (NSRX) has a BiotechSign Catalyst Score of 37/100, rated D. BiotechSign tracks available signal categories and recent signal records for this company, with clinical trial activity represented as a model score component separate from mapped trial-record counts. The BiotechSign score model uses available FDA-event records, clinical-trial activity, SEC insider filings, dilution-risk records, and sentiment inputs to calculate a catalyst grade.
Scope note: this signal page is not a complete drug pipeline, approved-product portfolio, FDA approval history, investigation history, or regulatory-event profile. It only renders the verified signal records currently mapped in BiotechSign.
This page displays automatically assembled records from BiotechSign data sources and may contain source-data errors or omissions. It is for informational purposes only, not financial advice, not medical advice, and not an investment recommendation. Do your own research and review the full disclaimer and terms of service.